Japanese researchers wrote about a myasthenia gravis (MG) patient who showed long-term improvement in disease symptoms after he was treated with blood purification therapy.
The case report, “A Case of Anti-MuSK Antibody-positive Myasthenia Gravis Successfully Treated With Outpatient Periodic Weekly Blood Purification Therapy,” appeared in Internal Medicine, the journal of the Japanese Society of Internal Medicine.
Myasthenia gravis is an autoimmune disorder characterized by the production of antibodies against the neurotransmitter acetylcholine receptor (AchR), a crucial protein for proper muscle function.
However, about 20 percent of MG patients do not exhibit anti-AchR antibody production. Of these, approximately 70 percent produce antibodies against muscle-specific tyrosine kinase (MuSK). Anti-MuSK antibodies affect clustering of AchR, leading to abnormal neuromuscular junctions.